Overview

Treatment for COVID-19 in High-Risk Adult Outpatients

Status:
Active, not recruiting
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the effectiveness of interventions on the incidence of lower respiratory tract infection (LRTI) progression among high-risk adult outpatients with SARS-CoV-2 infection to inform public health control strategies.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Washington
Collaborator:
Bill and Melinda Gates Foundation
Treatments:
Ascorbic Acid
Azithromycin
Folic Acid
Hydroxychloroquine
Lopinavir
Ritonavir
Vitamin B Complex